NRP/511 Week 3: Metabolic Syndrome Case, sample paper

A Normal BMI and a Waist That Tells a Different Story: The Pathophysiology of Metabolic Syndrome in a 38-Year-Old South Asian Software Engineer

[Student Name]

University of Phoenix

NRP/511: Advanced Pathophysiology

Week 3 Assignment

[Instructor Name]

[Date]

The patient is a composite written for a model paper.

Mr. P., a 38-year-old software engineer whose parents emigrated from Gujarat, India, comes for his first physical examination in five years. He considers himself healthy: his BMI is 24.1, and he walks on weekends. His waist circumference is 94 cm, his blood pressure 134/86 mm Hg, his fasting glucose 108 mg/dL, his triglycerides 212 mg/dL and his HDL cholesterol 36 mg/dL. His father had a heart attack at 52. This paper explains why a man of normal weight has metabolic syndrome and what is happening in his body.

Applying the Definition

The harmonized definition of metabolic syndrome requires three of five criteria: elevated waist circumference according to population- and country-specific thresholds, triglycerides of 150 mg/dL or higher, HDL cholesterol below 40 mg/dL in men or 50 mg/dL in women, blood pressure of 130/85 mm Hg or higher and fasting glucose of 100 mg/dL or higher (Alberti et al., 2009). The statement recommends a waist threshold of 90 cm or more for men of South Asian origin, lower than the 102 cm often used for men of European origin in the United States. Mr. P. meets all five criteria. Had his waist been judged by the 102 cm threshold, one criterion would have been missed, though he would still meet four.

Why Weight Misled

BMI measures weight relative to height but not where fat is stored. South Asian adults tend to have more visceral and liver fat, less muscle mass and greater insulin resistance than people of European origin at the same BMI, and they develop type 2 diabetes at younger ages and lower BMIs (Gujral et al., 2013). Mr. P.'s scale reading was normal because it weighed all of him; his risk lies in where the weight sits.

Visceral Fat as an Active Organ

Eckel et al. (2005) describe insulin resistance and central obesity as the core of the metabolic syndrome. Visceral fat cells, especially when enlarged, are more resistant to insulin's suppression of lipolysis. They release free fatty acids into the portal vein, which drains directly to the liver. They also secrete inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, and less adiponectin, a hormone that normally improves insulin sensitivity. The result is a flow of fatty acids and inflammatory signals that spreads insulin resistance to the liver and muscle.

Insulin Resistance in Muscle and Liver

In skeletal muscle, excess fatty acids and their metabolites interfere with insulin signaling, reducing glucose uptake after meals. In the liver, insulin normally suppresses glucose production; when the liver becomes resistant, it keeps producing glucose, raising fasting glucose. The pancreas responds by secreting more insulin, and for a time high insulin levels keep glucose near normal. Mr. P.'s fasting glucose of 108 mg/dL shows that compensation is beginning to fail.

How Insulin Resistance Produces the Lipid Pattern

The liver receives more fatty acids than it can burn and packages them into triglycerides, exported in very low-density lipoproteins. Triglycerides rise. Through exchange between lipoproteins, HDL particles become triglyceride-rich and are cleared faster, lowering HDL cholesterol, and LDL particles become smaller and denser, a more atherogenic form (Eckel et al., 2005). Mr. P.'s high triglycerides and low HDL reflect this sequence.

How It Raises Blood Pressure

High insulin levels increase sodium reabsorption in the kidney and activate the sympathetic nervous system. Visceral fat produces angiotensinogen, feeding the renin-angiotensin-aldosterone system. Endothelial dysfunction, driven by insulin resistance and inflammation, reduces nitric oxide-mediated vasodilation. Together these raise blood pressure.

Inflammation and the Vessel Wall

The chronic, low-grade inflammation of metabolic syndrome, combined with atherogenic lipids, high blood pressure and endothelial dysfunction, accelerates atherosclerosis. That is why metabolic syndrome roughly doubles the risk of cardiovascular disease, according to Alberti et al. (2009), and greatly increases the risk of type 2 diabetes.

Fatty Liver

Mr. P.'s liver enzymes are mildly elevated, with an alanine aminotransferase of 58 U/L. Liver fat is common in metabolic syndrome and particularly in South Asian adults (Gujral et al., 2013), and it both results from and worsens hepatic insulin resistance. I order an ultrasound and will calculate a fibrosis score.

Why the Syndrome Stays Silent

None of Mr. P.'s findings causes symptoms. Insulin resistance, high triglycerides, low HDL cholesterol, mildly raised blood pressure and early fatty liver are all silent, which is why he considered himself healthy. The damage accumulates in the vessel walls and liver for years before a heart attack, a diabetes diagnosis or liver scarring brings it to attention. This silence is the reason screening, and screening with the right thresholds, matters.

Testing the Mechanism in This Patient

Several further measures could confirm the picture. A fasting insulin level, used with fasting glucose to estimate insulin resistance, would likely be high. An A1C would show whether average glucose has also risen. A lipoprotein(a) level, which is often raised in South Asian adults and adds cardiovascular risk independently of the syndrome, would help refine his risk estimate. Each test would add information, but none would change the central message that his visceral fat and insulin resistance need treatment now.

Genetic and Early-Life Factors

Mr. P.'s family history of early heart disease adds genetic risk. Gujral et al. (2013) discuss possible contributions of genetic factors and of early-life influences, such as low birth weight followed by rapid weight gain, to South Asian adults' susceptibility.

Implications for Management

The mechanism points to the target: visceral fat and insulin resistance. Losing 5% to 7% of body weight, even in a man with a normal BMI, can reduce visceral fat disproportionately. Regular aerobic and resistance exercise improves insulin sensitivity in muscle independently of weight loss. Reducing refined carbohydrates and sugar-sweetened drinks lowers triglycerides. His blood pressure and lipids will be reassessed in three months, and his ten-year cardiovascular risk calculated with attention to his family history and ethnicity, which may favor statin therapy sooner.

Following Progress

Improvement can be measured by the same five criteria. A falling waist circumference, rising HDL cholesterol and falling triglycerides and fasting glucose would show that insulin resistance is easing. I will recheck these at three and six months and share the numbers with Mr. P. as a simple table, since seeing each component improve may help sustain the changes.

Screening His Family

His brother and sister, 35 and 32, should be screened for metabolic syndrome and diabetes, using the lower waist threshold.

Talking With Mr. P.

I explain the findings to Mr. P. in terms of his waist and his father's heart, not his weight, and he agrees to the plan.

Conclusion

Mr. P. has metabolic syndrome despite a normal BMI because his visceral fat, amplified by his South Asian heritage, drives insulin resistance in liver and muscle. Insulin resistance explains his high fasting glucose, high triglycerides, low HDL cholesterol and rising blood pressure, and chronic inflammation links them to early atherosclerosis. Population-specific waist thresholds, not weight alone, revealed the problem, and targeting visceral fat and insulin resistance is the way to reverse it.

References

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C., Jr. (2009). Harmonizing the metabolic syndrome. Circulation, 120(16), 1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644

Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. The Lancet, 365(9468), 1415-1428. https://doi.org/10.1016/S0140-6736(05)66378-7

Gujral, U. P., Pradeepa, R., Weber, M. B., Narayan, K. M. V., & Mohan, V. (2013). Type 2 diabetes in South Asians: Similarities and differences with white Caucasian and other populations. Annals of the New York Academy of Sciences, 1281(1), 51-63. https://doi.org/10.1111/j.1749-6632.2012.06838.x